BioSpace News Archive

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2020 following the close of market on Thursday, August 6, 2020.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2020 financial results will be released on Thursday, July 30, after the market closes.

Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAM™ (monomethyl fumarate), a novel fumarate for adults for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, will be commercially available in the U.S. September 1, 2020.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

McKesson announced that The Disability Equality Index has named the company as one of its 2020 Best Places to Work for Disability Inclusion with a top-ranking score of 100.

Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the U.S. financial markets.

Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the second quarter ended June 30, 2020, after the market closes on July 28, 2020.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), recently established the COVID-19 Prevention Network (CoVPN). I

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has granted a stock option to purchase 20,000 shares of common stock to one new employee.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that on July 15, 2020, the compensation committee of Seelos’ board of directors approved the grant of a stock option to purchase 50,000 shares of common stock to one new employee.